| 24025 |
Risankizumab |
Skyrizi® |
For the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, lost response to, or were intolerant to conventional or biologic therapy. The Applicant is seeking reimbursement in a subgroup of the licensed population, as second-line treatment after failure of the first biologic therapy. |
Rapid Review Complete |
6th August 2024 |
 |
| 19010 |
Risankizumab |
Skyrizi® |
Is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. |
Assessment Process Complete |
12th August 2021 |
|
| 21006 |
Risdiplam |
Evrysdi™ |
For the treatment of 5q spinal muscular atrophy (SMA) in patients 2 months of age and older, with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies. |
NCPE Assessment Process Complete |
20th October 2023 |
|
| 23071 |
Ritlecitinib |
Litfulo® |
For the treatment of severe alopecia areata in adults and adolescents 12 years of age and older. |
Pre submission consultation scheduled |
25th July 2024 |
|
| - |
Rituximab |
MabThera® |
Is indicated in adults for Non-Hodgkin’s lymphoma (NHL): Is indicated for the treatment of previously untreated patients with stage III-IV follicular lymphoma in combination with chemotherapy: As maintenance therapy for the treatment of follicular lymphoma patients responding to induction therapy: For the treatment of patients with CD20 positive diffuse large B cell non-Hodgkin’s lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. |
Rapid Review Complete |
24th September 2014 |
|
| - |
Rivaroxaban |
Xarelto® |
Rivaroxaban 10mg/day plus a P2Y12 inhibitor for stroke prevention due to NVAF in patients with renal impairment undergoing PCI with stent placement. |
Rapid Review Complete |
22nd November 2017 |
|
| - |
Rivaroxaban |
Xarelto® |
For the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events. |
Assessment Process Complete |
18th June 2019 |
|
| - |
Rivaroxaban |
Xarelto® |
For the prevention of stroke in atrial fibrillation. |
Assessment Process Complete |
19th June 2012 |
|
| - |
Rivaroxaban |
Xarelto® |
For the Primary Prevention of Venous Thromboembolic Events in Adult Patients who have Undergone Total Hip Replacement or Total Knee Replacement. |
Full HTA Assessment |
18th September 2008 |
|
| - |
Rivaroxaban |
Xarelto® |
For the Treatment of Deep Vein Thrombosis (DVT), and prevention of recurrent DVT and pulmonary embolism (PE) following an acute DVT in adults. |
Assessment Process Complete |
24th February 2012 |
|
| - |
Rivaroxaban |
Xarelto® |
Rivaroxaban 10mg daily for the prevention of recurrent venous thromboembolism in patients who have completed at least 6 months anticoagulation therapy for DVT or PE. |
Rapid Review Complete |
22nd November 2017 |
|
| - |
Roflumilast |
Daxas® |
For the maintenance treatment of severe Chronic Obstructive Pulmonary Disease associated with chronic bronchitis in patients with a history of frequent exacerbations. |
Full HTA Assessment |
3rd November 2010 |
|
| - |
Rolapitant |
Varuby® |
For the prevention of delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults. |
Rapid Review Complete |
13th June 2017 |
|
| - |
Romiplostim |
Nplate® |
Is indicated for chronic immune (idiopathic) thrombocytopenic purpura (ITP) in patients one year of age and older who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). |
Rapid Review Complete |
19th July 2019 |
|
| - |
Romiplostim |
Nplate® |
Is indicated for the treatment of adult chronic ITP splenectomised patients who have had either an inadequate response or who are intolerant of corticosteroids and immunoglobulins and also as second line treatment for adult ITP non-splenectomised patients where surgery is contraindicated. |
Rapid Review Complete |
27th May 2015 |
|
| 21016 |
Romosozumab |
Evenity® |
For the treatment of severe osteoporosis in postmenopausal women at high risk of fracture. |
NCPE Assessment Process Complete |
7th March 2023 |
|
| 23004 |
Ropeginterferon alfa-2b |
Besremi® |
Ropeginterferon alfa-2b is indicated as monotherapy in adults for the treatment of polycythaemia vera without symptomatic splenomegaly. |
NCPE Assessment Process Complete |
15th August 2024 |
|
| - |
Ropivacaine Readyfusor® |
Ropivacaine Readyfusor® |
For acute, postoperative pain management in adults. Readyfusor is used to maintain a continuous peripheral nerve block (CPNB) via a continuous infusion. |
Rapid Review Complete |
13th December 2018 |
|
| 21037 |
Roxadustat |
Evrenzo™ |
For the treatment of adult patients with symptomatic anaemia associated with chronic kidney disease. |
Rapid Review Complete |
6th October 2021 |
|
| - |
Ruxolitinib |
Jakavi® |
For the treatment of splenomegaly or disease-related symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. |
Assessment Process Complete |
9th July 2013 |
|
| 20008 |
Ruxolitinib |
Jakavi® |
For the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea. |
Assessment Process Complete |
21st July 2021 |
|
| 22007 |
Sacituzumab govitecan |
Trodelvy® |
Is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer who have received two or more prior systemic therapies, including at least one of them for advanced disease. |
NCPE Assessment Process Complete |
24th March 2023 |
|
| 23079 |
Sacituzumab govitecan |
Trodelvy® |
Sacituzumab govitecan is indicated for adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting. |
Rapid Review Complete |
26th January 2024 |
|
| - |
Sacubitril/valsartan |
Entresto® |
For the treatment of symptomatic chronic heart failure with reduced ejection fraction if adult patients. |
Assessment Process Complete |
8th July 2016 |
|
| - |
Safinamide methansulfonate |
Xadago® |
For the treatment of adult patients with idiopathic Parkinson’s disease. |
Rapid Review Complete |
6th July 2016 |
|
| - |
Sapropterin |
Kuvan® |
For the treatment of phenylketonuria (PKU). |
Full HTA Assessment |
15th September 2017 |
|
| - |
Sarilumab |
Kevzara® |
In combination with methotrexate (MTX) for the treatment of moderately to severely active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti-rheumatic drugs (DMARD). Sarilumab can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate. |
Rapid Review Complete |
4th October 2017 |
|
| - |
Sebelipase alfa |
Kanuma® |
Is indicated for long-term enzyme replacement therapy (ERT) in patients of all ages with lysosomal acid lipase (LAL) deficiency. |
Assessment Process Complete |
8th June 2018 |
|
| - |
Secukinumab |
Cosentyx® |
For the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy |
Rapid Review Complete |
16th December 2015 |
|
| - |
Secukinumab |
Cosentyx® |
For the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. |
Assessment Process Complete |
16th September 2015 |
|
| - |
Secukinumab |
Cosentyx® |
Alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate. |
Rapid Review Complete |
16th December 2015 |
|
| - |
Selexipag |
Uptravi® |
For the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II–III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies. |
Assessment Process Complete |
21st May 2018 |
|
| 21020b |
Selpercatinib |
Retsevmo® |
For the treatment of adult patients with advanced RET fusion-positive thyroid cancer who require systemic therapy following prior treatment with lenvatinib and/or sorafenib. |
Awaiting HTA submission from Applicant |
7th July 2021 |
|
| 21020a |
Selpercatinib |
Retsevmo® |
Is indicated for adult and adolescent patients, 12 years and older, with advanced RET-mutant medullary thyroid cancer (MTC) who require systemic therapy following prior treatment with cabozantinib and/or vandetanib. |
Awaiting HTA submission from Applicant |
7th July 2021 |
|
| 21021 |
Selparcatinib |
Retsevmo® |
For the treatment of adults with advanced rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy. |
Awaiting HTA submission from Applicant |
29th June 2021 |
|
| 22032 |
Selumetinib |
Koselugo® |
For the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in paediatric patients with neurofibromatosis type 1 (NF1) aged 3 years and above. |
Full HTA resubmission received 29/01/2024* |
6th November 2024 |
|
| - |
Semaglutide |
Ozempic® |
For the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise/as monotherapy when metformin is considered inappropriate due to intolerance or contraindications/in addition to other medicinal products for the treatment of diabetes |
Rapid Review Complete |
10th April 2018 |
|
| 20011 |
Semaglutide |
Rybelsus® |
For the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise: (a) as monotherapy when metformin is considered inappropriate due to intolerance or contraindications. (b) in combination with other medicinal products for the treatment of diabetes. |
Assessment Process Complete |
17th February 2021 |
|
| 22029 |
Semaglutide |
Wegovy® |
Is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of ≥30 kg/m2 (obesity), or ≥27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity e.g. dysglycaemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease. |
Rapid Review Complete |
9th June 2022 |
|
| - |
Sildenafil |
Revatio® |
(a) For the treatment of adult patients with pulmonary arterial hypertension classified as WHO functional class II and III, to improve exercise capacity. (b) For the treatment of paediatric patients aged 1 year to 17 years old with pulmonary arterial hypertension. |
Rapid Review Complete |
23rd May 2014 |
|
| - |
Simeprevir |
Olysio® |
In combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adult patients as part of a triple therapy regimen (co-administered with PegInterferon + Ribavirin) to treat hepatitis C virus (HCV) Genotypes 1 and 4 who are treatment naïve or have previously been treated. |
Rapid Review Complete |
11th July 2014 |
|
| - |
Simeprevir |
Olysio® |
In combination with Sofosbuvir for the treatment of chronic hepatitis C (CHC) in adult patients who are intolerant to or ineligible for interferon therapy, and are in urgent need of treatment. |
Assessment Process Complete |
13th March 2015 |
|
| 19053 |
Siponimod |
Mayzent® |
For the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity. |
Assessment Process Complete |
26th February 2021 |
|
| - |
Sodium Chloride 70mg/ml, Sodium Hyaluronate 1mg/ml |
Hyaneb® |
Is particularly indicated in patients with cystic fibrosis and in patients with bronchiectasis. Hyaneb® is classified as a medical device and carries a CE mark. |
Rapid review complete |
25th March 2014 |
|
| - |
Sodium Hyaluronate |
Hyloforte® 0.2% |
For the treatment of mild to moderate form of dry eye. |
Rapid review complete |
31st January 2014 |
|
| - |
Sodium Hyaluronate |
Hylotear® 0.1% |
For the treatment of mild to moderate form of dry eye. |
Rapid review complete |
31st January 2014 |
|
| 20043 |
Sodium hydrogen carbonate |
Thamicarb® |
For metabolic acidosis in chronic kidney disease. |
Rapid review complete |
23rd November 2020 |
|
| - |
Sodium phenylbutyrate |
Pheburane® |
As adjunctive therapy in the chronic management of urea cycle disorders, involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinate synthetase. |
Rapid review complete |
7th August 2013 |
|
| 24039 |
Sodium Zirconium Cyclosilicate |
Lokelma® |
Sodium Zirconium Cyclosilicate is indicated for the treatment of hyperkalaemia in adult patients. |
Rapid Review Complete |
6th November 2024 |
|
| - |
Sofosbuvir |
Solvaldi® |
In combination with other medicinal products for the treatment of Chronic Hepatitis C in adults. |
Assessment process complete |
13th November 2014 |
|
